Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Sponsor
Shanghai Chest Hospital
Study ID
NCT04895930
Phase
PHASE2
Status
Unknown

Conditions

  • Non-Small-Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Furmonertinib — DRUG
    80mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (40mg).
  • Anlotinib — DRUG
    10mg/day orally from day 1 to 14 of a 21-day cycle. If subjects suffer from AEs, they can get declined dosage (8mg).

Study Details

The aim of this phase Ⅱ study is to evaluate the efficacy and safety of Furmonertinib combined with Anlotinib as the first-line treatment in locally advanced or metastatic non-small cell lung cancer with sensitive EGFR mutations.

Key Dates

Start date
Oct 12, 2021
Status verified
Jan 2023
Primary completion
Nov 30, 2023
Completion
Nov 30, 2023

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Furmonertinib Plus Anlotinib
    Furmonertinib (80mg) plus Anlotinib (10mg)

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: Approximately 3 years following the first dose of study drugs ]

Central Contacts

Related Studies